Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3821 in advanced solid tumors
NCT06618651Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-3821 in solid tumor (advanced stage), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 3 weeks, Adverse Events at 1 year and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
SHR-3821
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06618651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618651.